A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

Biocon Ltd. has launched its drug-device combination for diabetes and obesity, Diavorin and Vobexoryn respectively, in the Netherlands via Pharmamedic BV.

While one of the drugs reportedly slated for fast-track review is the cholesterol pill Enlicitide Decanoate, the other is ...

Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...

For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.